PLEASE
READ: THE FOLLOWING FILES on this page ARE ARCHIVED FILES
AS WE HAVE MOVED TO ANOTHER FORMAT TO PRESENT NEW INFORMATION.
No one was more skeptical about using
Magnets for pain relief than Dr. Carlos
Vallbona, former chairman of the department of community medicine at Baylor
College of Medicine in Houston.
Matrix
metalloproteinase inhibitors
(MMPIs)
are effective in treating a mouse model of multiple
sclerosis.
The relationship between autobiographical Memory, Depression and quality of life (QoL) was
investigated in a study of 30 persons with severe neurodisability resulting
from multiple sclerosis.
1/01 Migraine
is a class of recurrent headache, sometimes preceded by an "aura."
Auras have been consistently tied to cortical spreading depression, during which
a wave of decreased brain cell activity crosses the cortex, the outermost part
of the brain.
2/00 Mitoxantrone for
injection concentrate was unanimously recommended for approval to slow the
worsening of neurologic disability and to reduce the relapse rate in patients
with clinically worsening forms of relapsing-remitting and
secondary progressive multiple sclerosis (MS).
2/00
Chemokines and matrix metalloproteinases
(MMPs)
appear to be crucial in leukocyte recruitment to the central nervous system
in multiple sclerosis (MS). CCR5 delta32, a
truncated allele of the CC chemokine receptor CCR5 gene encoding a
non-functional receptor, did not confer protection from MS.
2/00 The
central nervous system-specific myelin oligodendrocytic basic protein (MOBP)
is encephalitogenic and a potential target antigen in multiple sclerosis.
2/01
The MS Functional Composite
(MSFC), a recently developed outcome measure for MS clinical trials measuring
three dimensions (ambulation/leg function, arm/hand function, and cognition),
was applied to 134 patients with multiple sclerosis to study the concurrent
validity, using MRI measurements as a biological disease marker.
2/01
A significant correlation exists between disability and the volume of black
holes (BHL VOL), defined as hypointense lesions on T1-weighted cranial
magnetic resonance imaging.
2/01 We
compared the sensitivity of T2-weighted spin-echo (FSE)
and fast short-tau inversion-recovery (fSTIR) sequences in detection of multiple
sclerosis of the spinal cord in 100 consecutive patients with clinically
confirmed multiple sclerosis (MS); 86 patients underwent also brain MRI.
2/01 We
used high-resolution MRI to study the post-mortem
appearance of spinal cord multiple sclerosis in relation to histopathology
and low-resolution images.
Serial Magnetic Resonance
imaging in multiple sclerosis: correlation with attacks,
disability, and disease stage.
2/00 Fast fluid-attenuated
inversion-recovery
(FLAIR) and proton density/T2-weighted fast spin
echo (FSE) brain images with 3-mm slices were acquired monthly for 7 months in
37 multiple sclerosis patients.
8/99 Magnetic Resonance (MR) Imaging
is very sensitive in showing disseminated MS lesions. Subclinical MR
progression occurs frequently, explaining why MR is now used to monitor
treatment, even without measurable consequences, of new MR lesions to the
patient at this moment. In the light of this clinico-radiological paradox, the
significance of MR in MS is discussed, particularly in relation with the
expanded disability status scale (EDSS).
6/99 High-resolution pictures of stimulated brain regions
An Improved MRI
Technique allows a non-invasive study of the processing of visual stimuli
in anesthetized monkeys
4/21/99
TORONTO, April 21 /PRNewswire/NEWSdesk -- A study presented today at the
American Academy of Neurology annual meeting shows increasing evidence that
doctors can use
Magnetic
Resonance Imaging (MRI)
not only to diagnose multiple
sclerosis, but also to help predict the disease
course.
4/99 To assess practice effects, and
intrarater and interrater reliability of the MS functional composite
(MSFC) outcome measure.
MYELIN
The role of oligodendrocytes and oligodendrocyte progenitors in CNS
Remyelination.
8/3/99 A screen of candidates
from peaks of linkage: evidence for the involvement of myeloperoxidase in multiple
sclerosis.
2/01 Scientists
have successfully used frozen human cells taken from nerve
tissue to restore Nerve conduction in an
animal model of multiple
sclerosis.
4/99 The
fate of the neutralizing antibody (NAB)
in MS patients treated In the June issue of Nature,
researchers at Millennium BioTherapeutics have reported identifying a new
substance, calledn neurtactin, that shows up when inflammation occurs in the
brain. The substance apparently is part of a new family of chemokines and may
hold promise as a target for treatment
Neurotactin shows up in mouse brains after induction of autoimmune encephalomyelitis, a model for multiple sclerosis. It is associated with the surface of key cells.
2/00 NOVANTRONE(R) (mitoxantrone for injection
concentrate) was unanimously recommended for approval to slow the worsening of
neurologic disability and to reduce the relapse rate in patients with
clinically worsening forms of relapsing-remitting and
secondary progressive multiple sclerosis (MS).
First
Novantrone Phase III Results in Multiple Sclerosis
09:19 a.m. Sep 10, 1998 Eastern STOCKHOLM, Sweden, Sept. 10
/PRNewswire
7/98 The U.S. patent
will grant Amarillo Biosciences' claims to the use of low dose
Oral
Interferon in the treatment of multiple sclerosis
(MS)
PACLITAXELOctober 15, 1999 -- Patients with secondary progressive multiple sclerosis (SPMS) treated with monthly intravenous infusions of Angiotech's micellar Paclitaxel showed favourable trends in Expanded Disability Status Scale (EDSS) score, MS functional scores, quality of life and magnetic resonance imaging (MRI) burden of disease.
2/01 A
series of recently published articles by a group of Austrian, German and
American neuropathologists have proposed the existence of several different pathogenetic
pathways in multiple sclerosis (MS).
9/99 ROCHESTER, MINN. — Mayo Clinic neurologists
today reported the results of a new treatment option that was effective in over
40 percent of patients with
severe attacks of multiple
sclerosis and related diseases that cause inflammation and myelin
destruction in the brain and spinal cord.
4/00 Glutathione
S-transferase polymorphisms in MS: their relationship to disability.
4/00 Genetic
polymorphisms of immunorelevant genes may modulate occurrence or clinical features
of multifactorial diseases. PECAM-1 is an adhesion molecule crucial for transmigration of cells from blood
to tissues, but its genetic contribution to multifactorial diseases has never
been investigated. We have identified and characterized a tetranucleotide repeat
polymorphism within the third intron of PECAM-1.
5/99 Microsatellite polymorphisms in the gene promoter
of monocyte chemotactic protein-3 and analysis of the association between
monocyte chemotactic protein-3 alleles and multiple sclerosis development.
3/12/99 Molecules known as
Chemokines play a key role in inflammation of the
brain in
multiple sclerosis (MS) patients, according to
a report published in the March issue of the Journal of Clinical
Investigation.
Scientists have identified a
Protein that may trigger the friendly fire that damages nerves in multiple
sclerosis (MS). They hope that part of this protein eventually may be useful for
therapy.
1/00 On January 14 a results have been reported
of a positive new findings from recently completed clinical studies on fatigue
treatment with modafinil. Modafinil is being currently marketed as
Provigil in several countries, including the United States, for the treatment
of excessive daytime sleepiness (EDS) associated with
narcolepsy
REBIF 
5/4/00 A new
study compares two MS treatment options, Rebif and Avonex. The purpose is to
determine if there is a significant difference between higher-dose Rebif and
lower-dose Avonex Interferon Beta-1a therapy in relapsing-remitting MS. Each
product has been administered to thousands of patients worldwide. More
information
10/5/99 Ares-Serono International S.A. announced today that it has
initiated the first head-to-head study of interferon beta-1a treatment in
relapsing-remitting MS to determine if there are any differences between high-dose and low-dose interferon beta therapy
in
multiple sclerosis (MS).
Rothuizen L.E. et al published in a
recent edition of Journal of Neuroimmunology results of a single-blind,
placebo-controlled study with 24 healthy volunteers on the dynamics of
different biological markers upon receiving interferon-beta 1a
(Rebif)
or placebo for 29 days.
6/99
Update Key findings from the study included a reduction in the number and
severity of relapses suffered by patients, an increase in the number of patients
remaining relapse-free and a decrease in disease activity and burden of disease
as measured by magnetic resonance imaging (MRI).
3/2/99 On behalf of the entire MS Business Unit at Serono Laboratories,
I would like to Update you on the status of
Rebif® approval for the treatment of
Relapsing-Remitting Multiple Sclerosis in the United States.
3/2/99 Update:
Serono Laboratories, Inc. has received a Complete
response letter to its Biologics License
Application (BLA) for interferon beta-1a, Rebif. The agency has requested
clarification of clinical information and data. “Serono does not see any
difficulty in responding quickly to the FDA request for more information
necessary for tentative Rebif approval,” said Hisham Samra, M.D.,
president of Serono.
Laboratories.
3/1/99 Update:
Orphan Drug
Act.
Aers Serono's
Website,
MS-Network
(Link) aims at patients, their families, caregivers and professional
healthworkers involved in multiple sclerosis.
1/2000 Sexual dysfunction
affects a large
part of patients suffering from multiple sclerosis, but some htmlects of its
clinical presentation and aetiology are not clearly defined yet. In an
unselected sample of 108 patients with definite multiple sclerosis we
investigated the relationship between symptoms of sexual dysfunctioning and
sphincteric dysfunction, patients' and disease characteristics, disability and
neurological impairment, psychological and cognitive functioning.
1/2000 Sexual dysfunction is a very important but often
overlooked symptom of multiple sclerosis. To
investigate the type and frequency of symptoms of sexual dysfunction in
patients suffering from multiple sclerosis, we
performed a case-control study comparing 108 unselected patients with definite
multiple sclerosis, 97 patients with chronic
disease and 110 healthy individuals with regard to sexual function, sphincteric
function, physical disorders impeding sexual activity and the impact of sexual
dysfunction on social life.
Dr. Randall Schapiro's article on
MS and
Sexualtiy
4/98 Viagra®,
a new oral drug for impotence.
7/30/99
Transplant Cells Show Capacity For
Mending Nervous System
6/99
Transplanted
Neural Stem Cells Migrate
Throughout the Abnormal Brain,
Reduce
Disease Symptoms
1/99
The Department of Health and Human Services has concluded that current
law permits federal funds to be used for research utilizing human pluripotent stem cells. This decision is
consistent with existing congressional restrictions on human embryo research
and with federal law and regulations governing human fetal tissue
research.
1/26/99
Snyder's study validates a decade's worth of research into the cell
biology of brain development in mice. It also moves current attempts at
harnessing
Neural Stem
Cells for the treatment of human disease one step
closer to reality.
CHAMPAIGN, IL -- Oct.
2, 1998 -- STEROIDS
help to reduce inflammation, but University of Illinois scientists
suggest they also could be used to reverse a loss of myelin -- a major problem
in multiple sclerosis and other demyelinating diseases and injuries associated
with the central and peripheral nervous systems.
The
University of Copenhagen in Denmark conducted an eight-week study of the use of
high-dose Oral Steroid (methylprednisolone) by
51 patients with relapsing-remitting MS.
6/97 (3/97) This study suggests that oral
methylprednisolone is preferable to intravenous methylprednisolone for treatment
of relapses.
Abstract
1/13/97 Chronic
Prednisone
Use Causes Memory Loss In Patients With Systemic
Disease
10/96 Guidelines for the prevention of
Steroid Induced Osteoporosis
10/96 Effect
of Steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to
blood- brain barrier injury. June 96
UCSF/Mount Zion Researchers Find Correlation
Between
Stress and Disease Activity in Multiple Sclerosis
8/99 T
cell responses to myelin basic protein in patients with spinal cord injury and multiple
sclerosis.
6/99 A
New Method of permanently marking T cells has allowed Emory
University immunologists and colleagues to overcome one of the most
challenging barriers to understanding just how the immune system
works.
6/99 University of Illinois scientists have found a way to
improve the properties of
T-cell receptors -- and potentially other proteins. In doing so, they've opened the
door to manipulating a virtually untapped part of the immune system to fight
autoimmune and viral diseases.
1/7/97 The phosphodiesterase inhibitor
Pentoxifylline (Trental) reduces early
side effects of interferon-1b treatment in patients with multiple
sclerosis.
TRIGEMINAL NEURALGIA
6/99
A 27-year-old man who presented with clinical signs of a brainstem lesion developed
right-sided Trigeminal Neuralgia triggered by auditory
stimuli to the right ear.
The precise role of Tumor Necrosis Factor alpha
(TNFalpha) in
multiple sclerosis (MS) is still controversial.
1/99 Objective: To
investigate the effects of interferon beta treatment on T-cell tumor necrosis factor
(TNF) binding (which is a
possible marker for T-cell-dependent immune function) in patients with multiple
sclerosis.
Uric
Acid, a substance that naturally occurs in the body, has been shown to treat
a disease in mice that is similar to multiple sclerosis (MS), leading researchers
to hope that they can use the same or a similar compound in humans.
1/20/98
T-Cell
Vaccine study released.
Erectile dysfunction (ED) or impotence is a common and
disabling problem in men with multiple sclerosis. Recently, the FDA approved a
breakthrough oral medicine,
Viagra®
(sildenafil citrate) for the treatment of ED. UPDATE
6/98
Recently, it has been clearly demonstrated that exogenous
1,25-dihydroxyvitamin D3, the hormonal form of
Vitamin
D3 , can completely prevent experimental autoimmune
encephalomyelitis (EAE,), a widely accepted mouse model of human multiple
sclerosis (MS).
BACK to RESEARCH...PAGE 1
| Home | Doctors | Faqs | Library | Family | Boards | Forums | Webcast | Exchange | Support Group |
|
Your Multiple Sclerosis
Resource
|
International
MS Support Foundation |
|
Bluedomino A company with a heart who didn't think twice about helping with our efforts. Thank you staff for all of your helpful online support. Please show your appreciation by contacting them for your Internet needs. |
Copyright © 1996-2002 International MS Support Foundation |
Sponsored by public
contributions, a grant from Biogen
and long dedicated hours by volunteers with multiple sclerosis.
|
|
Email Jean ©1996-2002 International MS Support Foundation. All rights reserved. Disclaimer: This material is provided as general medical information only and may not include all side effects or details relevant to a particular individual's treatment. Answers are not intended as advice for individual patients; please contact your own physician/neurologist for specific recommendations. |
||